BioInformant

Your Global Leader in Stem Cell Market Research

Home » Stem Cell News » Press Releases » Page 21

Answer ALS Releases World’s Largest ALS Patient-Based iPSC and Bio Data Repository

By Leave a Comment

Unprecedented resource, created with Cedars-Sinai, to accelerate ALS research and drive development of targeted therapies globally

NEW ORLEANS –In a landmark continuing collaboration, Answer ALS and Cedars-Sinai have announced the completed availability of the largest amyotrophic lateral sclerosis (ALS) patient-based induced pluripotent stem cell (iPSC) and bio data repository. The repository encompasses biological and clinical data from nearly 1,000 ALS patients, offering an unprecedented resource for global researchers studying ALS, commonly known as Lou Gehrig’s disease. [Read more…]

Groundbreaking Discovery Unveils Damaging Effects of Lyophilization on Exosomes, with Major Implications for Regenerative Aesthetics

By 1 Comment

Rochester, NY – November 21, 2024 – A groundbreaking study on exosome lyophilization has revealed alarming insights about the process’s impact on the integrity and functionality of exosomes, unveiling major implications for the regenerative aesthetics industry. The findings were presented by Dr. Michael Heke, PhD, Managing Director and Scientific Officer at AT Venture Center™ at the 9th International Congress of Medical Excellence in Dermatology & Aesthetic Medicine (MEIDAM) in Dubai. This pivotal research, led by Dr. Carla Mazzeo, PhD, a globally recognized exosome expert with over 20 years of experience, brings to light critical flaws in current exosome preservation methods, particularly lyophilization (freeze-drying), a common technique used for creating shelf-stable exosome products. [Read more…]

EVerZom achieves first bioproduction of clinical grade stem cell-derived exosomes in large scale bioreactors in partnership with the French Blood Establishment (EFS) with unprecedented yields

By Leave a Comment

  • The disruptive, proprietary technology developed by EVerZom offers a yield 100 times higher than traditional methods.
  • This innovation has just been tech-transferred and validated in a GMP-grade biomanufacturing environment.
  • This first clinical batch will enable EVerZom to initiate regulatory non-clinical studies of its first drug candidate EVerGelTM.

[Read more…]

EXO-Harvest to launch breakthrough scalable fixed-bed bioreactor platform for MSC and EVs manufacturing

By Leave a Comment

Gosselies, Belgium, July 15, 2024 – EXO-Harvest, an affiliate of convEyXO, is thrilled to announce the successful launch of its cutting-edge multi-scale bioreactor platform for adherent cells and extracellular vesicles (EVs) production, in partnership with IPRATECH.  The platform is now fully operational, marking a significant milestone in joint efforts to advance biotechnological solutions through engineering excellence. [Read more…]

Takeda and Alloy Therapeutics to Co-Develop iPSC-Derived CAR-T and CAR-NK Products (iCAR-T and iCAR-NK)

By Leave a Comment

TOKYO & BOSTON — Alloy Therapeutics Inc. (“Alloy”), a biotechnology ecosystem company dedicated to democratizing access to cutting edge drug discovery technologies, announced today a strategic collaboration and license agreement with Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK “Takeda”) to develop Takeda’s proprietary induced pluripotent stem cell (iPSC) derived CAR-T cell platform (iCAR-T) and iPSC-derived CAR-NK platform (iCAR-NK). Alloy will focus on accelerating the development of key therapies to overcome solid and hematological malignancies. [Read more…]

Shopping cart0
There are no products in the cart!
Continue shopping
0